-Hindustan Times India’s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc’s patent application was rejected in January 2015. Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further. “By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,” said Henk...

-The Hindu Health-care workers at the primary level must be given the knowledge and skills to provide NCD and associated risk factor care. Noncommunicable diseases (NCD) such as diabetes, respiratory diseases, cancer and heart diseases are taking a severe toll on public health across the WHO South-East Asia Region. Approximately 8.5 million lives, many of them premature, are lost each year due to NCDs, making them the region’s leading cause of death...

-PTI Prices of 42 essential medicines used in treatment of various ailments including tuberculosis, cancer, cardiac diseases, asthma, epilepsy and depression have been capped by the government, reducing their cost by up to 15 per cent. Drug price regulator, National Pharmaceutical Pricing Authority (NPPA), in a notification on its website, said it “has fixed/revised ceiling prices of 45 scheduled formulations of Schedule-I under Drugs (Price Control) Amendment Order, 2016.” “Out of the 45,...

-The Times of India NEW DELHI: Drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) has slashed prices of 54 essential medicines by up to 55%, including commonly used drugs for cancer (brain and breast), hypertension, diabetes, antibiotics and other heart disorders. The move is aimed at bringing down prices of commonly used drugs for critical diseases by expanding span of price regulation to cover new drugs, NPPA Chairman Bhupinder Singh told TOI. In...

-The Hindu In the area of intellectual property, public health and access to medicines, the Narendra Modi government should consider its independence to be of the utmost importance. Strong government leadership as well as flexible intellectual property systems are needed in order to effectively combat drug-resistant tuberculosis (DR-TB) and HIV and also antimicrobial resistance and non-communicable diseases. This is true not only for India but also countries which rely on affordable generic...